Skip to content
DataLookout
Menu

BREnnANCT07413939

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

StatusRecruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 8 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 206 → 219 locations
  2. Notable Eligibility criteria expanded, about 14 words
    • Trial sites expanded: 186 → 206 locations
    • Secondary endpoints: details revised at 4 of 20 entries
  3. Minor Trial sites expanded: 152 → 186 locationsv9
  4. Minor Trial sites expanded: 109 → 152 locationsv8
  5. Minor Trial sites expanded: 55 → 109 locationsv7
  6. Notable Eligibility criteria expanded, about 5 words
    • Trial sites expanded: 4 → 55 locations
    • Start date changed from estimate of Jun 1, 2026 to May 21, 2026
    • Secondary endpoints: details revised at 4 of 20 entries
    v6
  7. Notable Recruitment openedv5 Show 4 more changesShow less
    • Start date: Apr 30, 2026 to Jun 1, 2026
    • Primary completion pushed from Mar 30, 2029 to May 1, 2029
    • Trial sites expanded: 0 → 4 locations
    • Study completion pushed from Aug 28, 2032 to Sep 29, 2032
  8. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-free Survival (PFS) as Determined by Blinded Independent Central Review (BICR)
Timeframe: Approximately 35 months

Secondary (20)

Progression-free Survival in Participants with Central Nervous System Metastases (PFS-CNS) by BICR
Overall Survival in Full Analysis Set (OS-FAS)
Objective Response Rate (ORR) by BICR
Duration of Response (DOR) as per BICR
Clinical Benefit Rate (CBR) as per BICR
Show 15 moreShow less
ORR in Participants with CNS Metastases (ORR-CNS)
DOR in Participants with CNS Metastases (DOR-CNS)
CBR in Participants with CNS Metastases (CBR-CNS)
Changes from Baseline in Symptoms Burden in Participants With Brain Tumors
Changes from Baseline in Function and Health-related Quality of Life (HRQoL)
Incidence of Adverse Events (AEs)
Severity of AEs
Change from Baseline in Echocardiogram (ECHO)/Multiple-gated Acquisition (MUGA)
Change from Baseline in the Columbia-suicide Severity Rating Scale (C-SSRS)
Number of Participants Reporting Presence, Frequency of Occurrence, Severity, and/or Degree of Interference With Daily Activities of Symptomatic Treatment Toxicities as Assessed Through Use of the Patient-reported Outcome (PRO)-CTCAE
Proportion of Participants Reporting Each Response Option at Each Assessment Timepoint by Treatment Arm for Treatment Side-effect Bother Single-item Functional Assessment of Cancer Therapy (FACT-GP5)
Change from Baseline/Worsening in Symptomatic Treatment Toxicities as Assessed Through Use of the PRO-CTCAE
Change from Baseline/Worsening in Symptomatic Treatment Side-effect Bother FACT-GP5
Health Utility Scores of the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L)
Plasma Concentration of RO7771950 and its Metabolite(s) at Specified Timepoints

Arms and interventions

Arm A - RO7771950 Dose Type 1Experimental
Arm B - RO7771950 Dose Type 2Experimental
Arm C - TucatinibActive comparator

Drugs: RO7771950, Tucatinib, Trastuzumab, Capecitabine

Sites

219 sites in 26 countries

China 26, United States 17, Italy 16, Spain 15, Turkey (Türkiye) 12, Germany 11, South Korea 10, Poland 9, United Kingdom 9, Belgium 8, Brazil 8, Canada 8, Portugal 8, Australia 7, France 7, Israel 7, Argentina 6, Chile 6, Thailand 6, Taiwan 5, Austria 4, Czechia 4, Hungary 3, Ukraine 3, New Zealand 2, South Africa 2